

The invention relates to novel solid body forms of mesoprogesterone 11 β - [4E - (hydroxy (methoxymethyl) - phenyl) - 17 α - methoxymethyl - 17 β - methoxy - estradiol - 4,9 - dien - 3 - one (oxime J 867), particularly a highly pure and stable amorphous or highly crystalline form (solvate/anhydrate) of compound J 867. The invention also relates to methods for producing said novel solid body forms and to the use thereof in pharmaceutical compositions. The novel solid body forms are characterized by exhibiting a high degree of stability. The solid body forms of oxime J 867 can, in particular, be used in the area of fertility control and in hormone replacement therapy.